Provider review
Sesame Care Review: One Page Says 14%, Another Says 25%
Sesame Care advertises the Wegovy pill with a number that is lower than the trial behind it: "Lose up to 14% of your weight" against OASIS 4's registered mean of 14.4%. That is genuinely unusual and this review says so. But one URL undoes it. Its weight-loss service page serves two hero variants, and the one we were shown seven times in ten reads "Lose up to 25% of your body weight" — no drug, no dose, no footnote, and above every registered mean on the page it sits on.
Sesame Care publishes two different answers to the same question, and which one you get is decided for you. Its Wegovy pill claim is the rare one on this site that needs defending rather than deflating: "up to 14%" against OASIS 4's registered 14.4%, for an FDA-approved product, which means the study tested what is actually dispensed. One variant of its weight-loss service page then prints "Lose up to 25% of your body weight" with no drug named, no dose, no footnote and no source — a figure higher than the posted result of every product on that page, Zepbound's 22.5% included. The other variant of the same URL is the most carefully sourced surface Sesame publishes, capping at 15% in twelve months and naming the trial population underneath. So the company is not consistently conservative and not consistently inflated; it is inconsistent, and the inconsistency lives inside one address. Sesame also sells care and medication as two separate prices, so the honest answer to what it costs is a sum it never prints.
Worth trusting if
- You have insurance, because Sesame prices the covered route beside the cash one and says its providers handle the prior authorization.
- You want the FDA-approved drug rather than a compounded copy, because approved medications are what its providers prescribe.
- You want to choose the clinician yourself, because the providers are listed by name before you book.
Be skeptical if
- You are deciding on the strength of the headline you happened to land on, because one variant of its weight-loss page promises 25% with no drug, dose or source named and the other caps at 15% with the trial population footnoted.
- You will not commit for a year, because the advertised monthly rate is the annual plan and month to month costs substantially more.
- You want one number to plan around, because the care subscription and the medication are billed separately and no page adds them together.
- You need to see your options before handing over credentials, because the intake demands an email and a password after two of its fifteen questions.
FDA-approved only
Phase 3 trials
Not named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens sesamecare.com. A link is not a recommendation to take anything.
Provenance
What Sesame Care actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
The finished product holds an FDA approval and carries an NDC. Approval covers the specific product, dose form and indication on the label — not the molecule in general.
- Wegovy® pill (oral semaglutide) — "Starting at just $149/month" for the pill, quoted separately from "access to GLP-1s & more, as low as $59/mo" for the care. Sesame charges for the care and the manufacturer's pharmacy channel charges for the drug, so a reader's real total is the sum. Doseworth prices this company in detail, including the fact that its program fee bills every 28 days rather than monthly.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
1
Molecules with human evidence
For the use they are sold for, out of 1 products reviewed here. The evidence belongs to the molecule, not to Sesame Care.
2
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Sesame Care’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Wegovy® pill (oral semaglutide)Semaglutide · FDA-approvedClaim matches the trials
“GLP-1 weight loss, now in pill form. Lose up to 14% of your weight with the Wegovy® pill, starting at just $149/month. No needles required. […] Weight loss medication — Online weight loss care, access to GLP-1s & more, as low as $59/mo.”
Read on the Sesame Care site, August 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT05564117 OASIS 4 — Phase 3, completed, n=307. Oral semaglutide 25 mg in adults with overweight or obesity. Registry-verified 2026-08-11: primary outcome "Percentage Change in Body Weight", reported as −14.4% on oral semaglutide against −2.5% on placebo. The drug-attributable difference is about 11.9 percentage points.
- NCT05035095 OASIS 1 — Phase 3, completed, n=667. The larger sibling trial, testing oral semaglutide at 50 mg rather than 25 mg, with the same primary outcome. Included because it is the other registered oral-semaglutide obesity trial and a reader checking the claim will find it — it is not the dose behind the Wegovy pill.
The number is right, the product is right, and the direction of the error is one this site almost never sees. OASIS 4 reported a mean 14.4% reduction in body weight on oral semaglutide 25 mg; Sesame advertises "up to 14%". A company inclined to overstate had room to claim more and did not. Two qualifications belong on it. First, "up to" is the wrong quantifier for a mean: 14.4% was the average result, so roughly half the trial's participants lost more than 14% and the phrasing implies a ceiling where the trial reported a midpoint. Second, the placebo arm lost 2.5%, so the effect attributable to the drug is about 11.9 percentage points rather than the full 14 — a distinction no seller in this category makes, and one worth holding on to when comparing any two of these numbers. This verdict covers this claim, on the two surfaces it was read from — the home page and /medication/wegovy-pill, both re-read on 26 August 2026 and both still saying 14%. It does not cover the company's weight-loss marketing as a whole, and it should not be read that way: a variant of /service/online-weight-loss-program carries an unsourced "Lose up to 25% of your body weight" that names no drug at all, and the same variant's card for this product reads "Lose 14-17%" before restating 17% as an average for adults who continued treatment. That 17% has no registered mean behind it: a sweep of the 50 oral-semaglutide studies filed under an obesity or overweight condition, run 2026-08-26, found three with a posted mean weight change — 14.4%, 15.8% and 14.9% — and the two above 14.4% were run at 50 mg, a dose this product is not sold at. A claim that names its product and lands under its trial is not evidence about a claim that names nothing.1
Dispensing chain
Who actually fills your prescription
Read the full account
Sesame is a marketplace rather than a compounder, and states the arrangement plainly: "Sesame-affiliated provider practices are independently owned and operated by licensed clinicians who provide clinical services using the Sesame telehealth platform." Its headline GLP-1 offer is an FDA-approved finished drug dispensed through the manufacturer's own pharmacy channel, so the question this field usually asks — which compounding pharmacy made this — does not arise for that product in the way it does elsewhere on this site. No compounding pharmacy is named because no compounded preparation is the subject of the claim reviewed here.
Read on the Sesame Care site, August 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, lot number or potency result is published, and for the product reviewed here that is the expected answer rather than a gap: an FDA-approved finished drug carries its manufacturer's own quality system and an NDC, so batch documents are not something a telehealth marketplace would hold or publish. This field would matter if Sesame sold a compounded preparation under its own name; the claim reviewed here is for an approved product.
Read on the Sesame Care site, August 2026.
Licensing
Licensed to dispense, and where
Coverage
Sesame publishes no state list, included set or excluded set for its weight-loss service on the surfaces reachable without an account, so there was nothing we could check ourselves, and no coverage is claimed below.
Read the full licensing claim
"Sesame-affiliated provider practices are independently owned and operated by licensed clinicians who provide clinical services using the Sesame telehealth platform." Sesame states it is the platform and not the practice, which is a clearer separation than most of the companies we track draw.
Read on the Sesame Care site, August 2026.
Regulatory
The FDA warning letter
Checked, and none found
We did this ourselves
What happens when you sign up with Sesame Care
We went through Sesame Care’s signup ourselves in August 2026 to find out what you actually meet before you pay — the steps, when a price appears, and what it asks for. We used placeholder answers, and we stopped before paying, so nothing here is a prescription or a medical outcome. It is what the screens showed.
- Read the weight loss page, which prints the care price, every medication's cash price and its with-insurance price before anything is asked.
- Press Get started, which opens a fifteen-question program questionnaire.
- Pick your weight loss goals from six options, choosing as many as you like.
- Read a screen telling you your goal is closer than you think, and press through to the measurements.
- Give your height, weight, date of birth and sex assigned at birth.
- Watch it draw a twelve-month projection to a goal weight, then press continue.
- Create an account with an email address and a password, and agree to the terms, before it will show any treatment option or ask the remaining questions.
- The prices arrive long before the intake does, and there are a lot of them. The care subscription, the cash price of each medication and the with-insurance price all sit on the weight loss page together.
- The advertised monthly rate for care is an annual commitment. Paying month to month is $99, and the page says the annual plan saves $480 a year against exactly that figure.
- Medication is billed separately and its ladder is steep. The Wegovy pen is $199 a month for the first two months for new patients and $349 after — re-read 2026-08-26 and unchanged, on the medication table, the drug page and the promotional terms alike. Two conditions the headline leaves out: the introductory rate applies only at the two lowest dose strengths, and the $349 that follows applies to every dose.
- The Zepbound pen climbs with every dose step, and the steps are published: $299 a month at the lowest strength rising to $698 at the top three. A patient who titrates to the dose the trials used ends up paying the highest figure on the ladder.
- The card prices and the ladder are different products, which is easy to misread. The tiles at the top of the weight loss page start the Wegovy pill at $149 a month — the price of its two lowest doses, where the higher doses are $299. The pen is a separate row starting at $199. No tile shows what the dose you end up on will cost.
- Insurance changes the picture more than any of this. Every medication on the table is quoted as low as $25 a month with coverage, against cash prices running from $149 to $1,086.
- The intake stops at a wall after two of its fifteen questions. It wants an email address and a password before it will show a single treatment option, with the other thirteen still unasked. We stopped there.
- Before that wall it draws a projection from four inputs — height, weight, date of birth and sex — showing a goal weight twelve months out, with nothing to compare it against.
- The other way in is a chat assistant that asks height and weight and then quotes the care price, on a program whose own page promises no chatbots, just real doctors and practitioners.
Sesame Care support
- Phone
- 1 (877) 947-6411
- Hours
- Monday to Friday, 9 am to 9 pm Eastern
Assessment
What holds up, and what does not
- Its Wegovy pill claim is lower than the trial it comes from — "up to 14%" against a registered mean of 14.4% — which is the opposite of the error this site usually documents.
- One variant of its weight-loss page footnotes its milestones to the trial population — "a study of injectable semaglutide 2.4 mg in non-diabetic adults with obesity (BMI≥30) or overweight (BMI ≥27 with ≥1 weight-related condition), when paired with healthy lifestyle changes" — which is more sourcing than almost any company reviewed here publishes.
- Its drug page states the quantifier correctly where the hero does not: "lost an average of about 14% of their body weight over 64 weeks".
Show 5 more
- The product behind the claim is FDA-approved, so the trial tested the thing being sold rather than a branded analog of it.
- It names the product outright — the Wegovy® pill — rather than selling "a GLP-1" of unstated molecule, which several companies reviewed here do.
- It states plainly that it is a platform and that the clinical practices are independently owned, rather than implying it employs the clinicians.
- The care price and the medication price are quoted as separate figures rather than merged into one number that hides which is which.
- No FDA warning letter for Sesame Care as of 11 August 2026.
- One variant of its weight-loss service page reads "Lose up to 25% of your body weight" with no drug, no dose and no source — a figure above every registered mean on that same page, including Zepbound's.
- Which figure a reader sees depends on which render of that one URL they are served: ten loads on 26 August 2026 returned the 25% variant seven times and the sourced variant three times.
- The two variants disagree with each other. The sourced one caps at "In 12 months Lose 15% of your body weight" and footnotes the trial population; the other says 25% and footnotes nothing.
Show 7 more
- A third figure sits on the same page. The Wegovy pill card in the sourced variant reads "Lose 14-17%", and lower down the same card states 17% as an average: adults "who continued treatment with Wegovy® pill lost an average of 17% of their weight".
- No registered mean of 17% exists for the Wegovy pill. Of 50 oral-semaglutide studies listed under an obesity or overweight condition in August 2026, three post a mean weight change — 14.4% at 25 mg, 15.8% at 50 mg and 14.9% at 50 mg — and the pill is not sold at 50 mg.
- "Up to 14%" attaches a ceiling quantifier to what was a mean result, so the phrasing misdescribes the shape of the evidence even though the magnitude is conservative.
- The placebo arm in OASIS 4 lost 2.5%, and no marketing number anywhere in this category is net of that — the drug-attributable difference is about 11.9 points, not 14.
- No trial is named on the page, so a reader cannot check the 14% against anything without knowing which study to look for.
- The advertised "$149/month" for the pill and "as low as $59/mo" for the care are quoted separately and never added together, so no single figure on the page is what a patient actually pays.
- No state list is published on the surfaces reachable without an account.
Verdict
The bottom line
Where Sesame names the drug it is honest, and sometimes conservative — "up to 14%" for the Wegovy pill sits under the 14.4% its trial reported. Where it names no drug, the number climbs to 25% and nothing on the page will tell you where that came from. Check which figure you were shown, and whether anything underneath it says what was studied.
Opens sesamecare.com. A link is not a recommendation to take anything.
The same page, two different numbers
Start with the finding that arrived last, because it changes how the rest reads.
`/service/online-weight-loss-program` does not serve one page. It serves two, and we were shown both. Ten loads in clean browser contexts on 26 August 2026 returned the first variant seven times and the second three times.
Variant one — headed "Lose weight with GLP‑1s and top‑rated care" — puts three bullets under the price block:
"Lose up to 25% of your body weight · Access to FDA-approved GLP-1 options · Delivery or same-day pickup available, if prescribed"
No drug is named. No dose. No trial, no footnote, no asterisk, nothing anywhere on the page that says where 25% comes from.
Variant two — headed "Access top-rated care & weight loss medication online" — is the opposite, and it is better than almost anything else in this category:
"Results from our telehealth weight loss program. In 3 months Lose 5% of your body weight. In 6 months Lose 10% of your body weight. In 12 months Lose 15% of your body weight."
>
"Results may vary. Milestones are based on a study of injectable semaglutide 2.4 mg in non-diabetic adults with obesity (BMI≥30) or overweight (BMI ≥27 with ≥1 weight-related condition), when paired with healthy lifestyle changes."
That footnote names the molecule, the dose, the route, the enrolled population and the lifestyle condition. Very few companies reviewed on this site publish that much.
So one address holds Sesame's most disciplined claim and its least disciplined one, and a reader has no way to know which they were served.
Full analysis — 7 more sectionsWhere 25% sits against the registry · The third figure, and where 17% is not · What this does to the rest of the review · A claim below its own evidence · Where the framing still goes wrong · The part that makes this review different · What it is, and what that means for price
Where 25% sits against the registry
Sesame lists six medications on that page. The strongest of them is Zepbound, and tirzepatide's obesity trial has posted results: SURMOUNT-1 (NCT04184622) reports a least-squares mean change in body weight of −22.5% at 15 mg, −21.4% at 10 mg and −16.0% at 5 mg, against −2.4% on placebo. 2
Nothing on the page has a registered mean of 25%. The Wegovy pill the same site advertises at 14% is well below it. Sesame's own other variant caps at 15% in twelve months, and footnotes that to injectable semaglutide 2.4 mg.
The third figure, and where 17% is not
A third figure sits on the sourced variant's listing for this very product:
"Lose 14-17% of your body weight with proper nutrition and exercise."
Read further down the same card and 17% stops being the top of a range and becomes a mean:
"Clinical trials have shown that Wegovy® pill can lead to an average weight loss of 14% after 64 weeks when combined with lifestyle modifications… Adults who continued treatment with Wegovy® pill lost an average of 17% of their weight."
That is a specific, checkable claim, so it was checked. In August 2026 the registry lists 50 studies naming oral semaglutide as an intervention under an obesity or overweight condition. Exactly three post a mean percentage change in body weight: 4
- NCT05564117 (OASIS 4), oral semaglutide 25 mg, 307 participants — the dose the Wegovy pill maintains on: −14.4%, against −2.5% on placebo
- NCT05035095 (OASIS 1), oral semaglutide 50 mg, 667 participants: −15.8%, against −2.2%
- NCT05132088, oral semaglutide 50 mg in East Asian adults, 201 participants: −14.9%, against −1.5%
The highest mean in the whole program is 15.8%, and it belongs to a 50 mg dose. Sesame's own page lists the pill's doses as 1.5, 4, 9 and 25 mg. There is no 50 mg Wegovy pill to buy, and there is no registered 17%.
It is worth being precise about which program applies, because the obvious near-miss is a different disease. OASIS is the oral-semaglutide obesity program and every one of its trials carries the conditions "Overweight" and "Obesity". PIONEER is the oral-semaglutide type 2 diabetes program — thirty of its records return under a type 2 diabetes condition, and the only one that also surfaces on an obesity query, PIONEER START, is itself registered under "Diabetes Mellitus, Type 2". A diabetes trial is not evidence for a weight-loss claim.
The phrase "who continued treatment" is the tell, and it points at a real statistical practice: results calculated on the people who stayed on the drug run higher than results calculated on everyone randomized, because the ones who stopped are the ones it suited least. That is a plausible origin for 17%. It is not one this review can confirm, no such figure appears in the registry, and so no number is offered here in its place — only the observation that the one on the page is not in the record.
What this does to the rest of the review
This review was published on the finding that Sesame understates — and on the surfaces where it names the drug, it still does. Both were re-read on 26 August 2026 and neither had moved:
`/medication/wegovy-pill`: "Lose up to 14% of your body weight with the Wegovy pill, the first-ever oral GLP-1 medication for weight loss" — and, further down the same page, the quantifier stated correctly: "people taking a once-daily 25 mg dose of oral semaglutide (the maximum dose of Wegovy) lost an average of about 14% of their body weight over 64 weeks."
The home page's sentence, quoted in full in the next section, is unchanged too.
That is a real and unusual virtue and this page keeps saying so. What it can no longer say is that understating is a property of the company. The honest version is narrower and more useful: where Sesame names the drug, its number is careful and sometimes conservative; where it names no drug, the number is 25% and nothing supports it. Those are not two readings of one habit. They are two different pieces of marketing that happen to share a domain, and one of them is served to most visitors.
A claim below its own evidence
Sesame's home page carries one efficacy number:
"GLP-1 weight loss, now in pill form. Lose up to 14% of your weight with the Wegovy® pill, starting at just $149/month. No needles required."
The trial behind the Wegovy pill is OASIS 4 (NCT05564117) — oral semaglutide 25 mg in adults with overweight or obesity. Verified in the registry on 11 August 2026:
- Status — Completed
- Phase — 3
- Participants — 307
- Primary outcome — Percentage change in body weight
- Result — −14.4% on oral semaglutide, against −2.5% on placebo
So the advertised figure is below the registered result. On a site that spends most of its time documenting claims that reach past their evidence, this is worth stating plainly: Sesame had room to claim more and did not.
Where the framing still goes wrong
"Up to 14%" describes a ceiling. 14.4% was a mean. Those are different statements about the same trial, and the difference matters in both directions: about half the participants lost more than 14.4%, and a substantial number lost considerably less. A reader told "up to 14%" will reasonably plan for less than 14% and may be surprised in either direction.
The second qualification applies to every number in this category and is almost never made. The placebo arm in OASIS 4 lost 2.5% of body weight. The effect attributable to the drug is therefore about 11.9 percentage points, not 14.4. Every trial in this class enrolls people into a program of diet and activity support alongside the drug, and that program does some of the work.
The part that makes this review different
Nearly every claim assessed on this site carries the same caveat: the trial tested an FDA-approved product, and the company dispenses a compounded preparation that has never been through a registered trial.
That caveat does not apply here. The Wegovy pill is an approved finished drug with an NDC, dispensed through the manufacturer's own channel. Whatever else is true of Sesame's marketing, the study behind its number tested the thing it is selling.
What it is, and what that means for price
Sesame states its own structure clearly:
"Sesame-affiliated provider practices are independently owned and operated by licensed clinicians who provide clinical services using the Sesame telehealth platform."
It is a marketplace. It charges for access to care — "as low as $59/mo" — and the medication is billed separately at "$149/month". Neither number is the cost of treatment; the sum is, and the page never prints it.
Questions
Frequently asked questions
Where does Sesame's "up to 25%" figure come from?
Nowhere the page will tell you. One of two hero variants served at sesamecare.com/service/online-weight-loss-program carries the bullet "Lose up to 25% of your body weight", with no drug named, no dose, no trial and no footnote. Ten loads in clean browser contexts on 26 August 2026 returned that variant seven times; the other three returned a variant whose milestones stop at "In 12 months Lose 15% of your body weight" and are footnoted to "a study of injectable semaglutide 2.4 mg in non-diabetic adults with obesity (BMI≥30) or overweight (BMI ≥27 with ≥1 weight-related condition), when paired with healthy lifestyle changes." The 25% is also above every registered result on the page it sits on: the strongest product listed there is Zepbound, and SURMOUNT-1's posted results are a least-squares mean of −22.5% at 15 mg. Sesame's own Wegovy pill claim, on its home page, is 14%.
Does Sesame understate or overstate its weight-loss numbers?
Both, on different pages, and this review used to say only the first. Where Sesame names the product, it is careful: "up to 14%" for the Wegovy pill against OASIS 4's registered mean of 14.4%, and its drug page even fixes the quantifier, saying patients "lost an average of about 14% of their body weight over 64 weeks". Where it names no product, the number is "up to 25% of your body weight" with nothing behind it. A third figure, "Lose 14-17%", sits on the Wegovy pill card of the sourced variant, restated lower down as an average for adults who continued treatment — and no registered trial reports a mean of 17% for this product. The useful conclusion is not a direction but a rule: read the figure that names a drug and a dose, and treat the one that names neither as advertising.
Is there a trial showing the Wegovy pill produces 17% weight loss?
Not in the registry. Sesame's Wegovy pill card advertises "Lose 14-17%" and then states that adults "who continued treatment with Wegovy® pill lost an average of 17% of their weight". A sweep of ClinicalTrials.gov in August 2026 found 50 studies naming oral semaglutide as an intervention under an obesity or overweight condition, of which three post a mean change in body weight: 14.4% at 25 mg in 307 participants, 15.8% at 50 mg in 667, and 14.9% at 50 mg in 201 East Asian adults. The highest is 15.8% and it comes from a 50 mg dose; Sesame lists the pill's doses as 1.5, 4, 9 and 25 mg, so that trial is not testing what is being sold. The matching program is OASIS, which studies oral semaglutide in overweight and obesity — not PIONEER, which studies the same drug in type 2 diabetes. The phrase "who continued treatment" suggests a result calculated only on the people who stayed on the drug, which runs higher than a result calculated on everyone enrolled, but that is an inference and this site does not put a number of its own against the one on the page.
Is "lose up to 14%" accurate?
It is conservative, which is unusual here. OASIS 4 (NCT05564117), the phase 3 trial of oral semaglutide 25 mg in 307 adults with overweight or obesity, reported a mean weight change of −14.4% against −2.5% on placebo. Sesame advertises "up to 14%", a number below its own evidence. The framing is still imprecise: "up to" implies a ceiling where the trial reported an average, so roughly half the participants lost more. And no advertised figure in this category is net of the placebo arm — the drug-attributable difference here is about 11.9 percentage points.
Is the Wegovy pill the same as compounded semaglutide?
No, and the difference runs the right way for once. The Wegovy pill is an FDA-approved finished drug with a manufacturer's quality system behind it, so OASIS 4 tested the product Sesame is selling. Almost every other claim reviewed on this site has to carry the opposite caveat — that the trial tested the approved drug while the seller dispenses a compounded preparation that has never been through a registered trial of any kind.
What does Sesame actually cost?
Two numbers that are never added together: "as low as $59/mo" for the weight-loss care and "starting at just $149/month" for the pill. A patient pays both. Doseworth prices this company in detail, including the fact that Sesame's program fee bills every 28 days rather than monthly — which makes a year thirteen charges rather than twelve.
Has Sesame Care had an FDA warning letter?
No. FDA's live warning-letter index was queried on August 11, 2026 for "sesame care". It returned five rows, and their company columns read Revolution Foods PBC, Sanitation & Environmental Technology Institute dba SDWH, Ayuryoga Inc. and two others — the phrase matched inside letters addressed to other businesses. A query for "strut" in the same pass returned Strut Health's real letter, which is what makes this zero evidence rather than a sign of a broken search.
Glossary
Key terms
Show definitions
- Hero variant
- One of two or more versions of the same page, served to different visitors at the same address. It is ordinary practice for testing a design, and it becomes a reporting problem when the versions make different factual claims — because no single reading of the URL is the page, and a reader cannot tell which one they were given.
- "Up to"
- A ceiling. When a trial reports a mean, roughly half the participants fall above it and half below, so "up to the mean" describes neither the typical result nor the maximum. It is the most common quantifier in this category and almost always the wrong one.
- Placebo-adjusted effect
- The difference between what the treatment arm lost and what the placebo arm lost. In OASIS 4 that is 14.4% minus 2.5%, or about 11.9 percentage points. Marketing figures in this category are gross rather than placebo-adjusted, which flatters every drug in it equally.
- FDA-approved finished drug
- A product that has been through the approval process and carries an NDC, manufactured under the sponsor's own quality system. Distinct from a compounded preparation, which is made for an individual patient by a pharmacy and has not been evaluated by FDA for safety, effectiveness or quality.
Compare
Others selling what Sesame Care sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Sesame Care's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 5 sources
- Knop FK, Aroda VR, do Vale RD, et al. (2023). Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 402(10403):705-719. https://pubmed.ncbi.nlm.nih.gov/37385278/
- US National Library of Medicine (2026). SURMOUNT-1 (NCT04184622, phase 3, completed, n=2,539) posted results, read from the registry's results section on 2026-08-26. Primary outcome "Percent Change From Baseline in Body Weight", least-squares mean: −22.5% on tirzepatide 15 mg, −21.4% at 10 mg, −16.0% at 5 mg, against −2.4% on placebo. Zepbound is the strongest product Sesame lists on the page carrying the 25% figure, and this is its registered result.. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT04184622?tab=results
- Peptideworth (2026). First-hand capture of the two hero variants of sesamecare.com/service/online-weight-loss-program, 2026-08-26. Ten loads in separate clean browser contexts returned the "Lose weight with GLP‑1s and top‑rated care" variant, whose hero bullet reads "Lose up to 25% of your body weight", seven times, and the "Access top-rated care & weight loss medication online" variant, whose milestones cap at "In 12 months Lose 15% of your body weight" under a footnote naming injectable semaglutide 2.4 mg and the enrolled population, three times. The home page and /medication/wegovy-pill were re-read in the same session and both still carry "up to 14%".. Peptideworth site capture. the Sesame Care site
- US National Library of Medicine (2026). ClinicalTrials.gov v2 sweep for a registered mean of 17% for oral semaglutide in obesity, run 2026-08-26. Intervention "oral semaglutide" filtered to an obesity or overweight condition returns 50 studies; three post a mean percentage change in body weight — NCT05564117 (OASIS 4, 25 mg, n=307) −14.4% against −2.5%; NCT05035095 (OASIS 1, 50 mg, n=667) −15.8% against −2.2%; NCT05132088 (50 mg, East Asian adults, n=201) −14.9% against −1.5%. No study reports 17%. PIONEER, the oral-semaglutide type 2 diabetes program, returns 30 records under a type 2 diabetes condition; its only obesity-query match, NCT05444153 (PIONEER START), is itself registered under "Diabetes Mellitus, Type 2". Controls in the same pass: 180 studies for tirzepatide under an obesity condition, 0 for a fabricated molecule name.. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT05564117?tab=results
- Peptideworth (2026). First-hand capture of Sesame's medication pricing table, 2026-08-26, read from the sourced variant of sesamecare.com/service/online-weight-loss-program and cross-checked against sesamecare.com/medication/wegovy and the promotional-terms block rendered on both hero variants. Wegovy pen, transcribed rather than bound so that a later price edit cannot rewrite what Sesame published: “Starts at $199 /mo … Price without insurance: $199 /mo. for first two months (new Wegovy® patients only), then $349/mo after.” The terms block limits the introductory rate to “the lowest available dosage strengths (0.25 mg or 0.5 mg)” and applies the standard rate to all Wegovy doses thereafter, with the offer effective from 2025-11-17. Wegovy pill: $149 a month at 1.5 mg and 4 mg, $299 at 9 mg and 25 mg. Zepbound KwikPen by dose step: $299, $398, $499 and $698 a month. Zepbound vial $299; branded Zepbound $1,086. Every row is quoted as low as $25 a month with insurance.. Peptideworth site capture. the Sesame Care site
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.